Holen Sie sich die Stockscreener-App
25.52
0.55%
0.205
Castle Biosciences Inc Aktie (CSTL) Neueste Nachrichten
Stokes Frank sells Castle Biosciences (CSTL) stock worth $192k - Investing.com Nigeria
Castle Biosciences Inc (CSTL) CFO Frank Stokes Sells 6,001 Shares - GuruFocus
Insider Selling: Castle Biosciences (NASDAQ:CSTL) CFO Sells 6,001 Shares of Stock - MarketBeat
Insider Selling: Castle Biosciences (NASDAQ:CSTL) Director Sells 7,403 Shares of Stock - MarketBeat
DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest - GlobeNewswire
DecisionDx®-Melanoma’s i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk - Sahm
Aug Wrap: Whats next for Castle Biosciences Inc stockVolume Spike & Expert Verified Movement Alerts - baoquankhu1.vn
Death Cross: Will Castle Biosciences Inc benefit from current market trendsEarnings Growth Summary & Low Volatility Stock Suggestions - baoquankhu1.vn
How Castle Biosciences (CSTL) Story Is Shifting With New Revenue Targets And Fair Value - Yahoo Finance
Stokes Frank sells Castle Biosciences (CSTL) stock worth $192k By Investing.com - Investing.com India
Frank Stokes Sells 7,000 Shares of Castle Biosciences (NASDAQ:CSTL) Stock - MarketBeat
Castle Biosciences: Interview With Founder, CEO, And President Derek Maetzold About The Molecular Diagnostics Company - Pulse 2.0
Castle Biosciences Stock Hits Day Low of $27.22 Amid Price Pressure - Markets Mojo
Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma’s i31-SLNB, Identifying T1b-T2a Melanoma Patients Who May Safely Avoid SLNB - The Manila Times
Castle Biosciences to Present Data at SSO 2026 on - GlobeNewswire
Castle Biosciences (NASDAQ:CSTL) Lowered to Hold Rating by Zacks Research - MarketBeat
Castle Biosciences to Present Data at SSO 2026 on DecisionDx-Melanoma's i31-SLNB, Identifying T1b-T2a Melanoma Patients Who May Safely Avoid SLNB - Bitget
Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas - Bitget
CSTL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Canaccord reiterates Castle Biosciences stock rating on Q4 beat By Investing.com - Investing.com India
Canaccord reiterates Castle Biosciences stock rating on Q4 beat - Investing.com Nigeria
Aug Volume: What is the target price for Seer Inc stockEarnings Beat & Community Shared Stock Ideas - baoquankhu1.vn
Q4 2025 Castle Biosciences Inc Earnings Call Transcript - GuruFocus
Castle Biosciences, Inc. (NASDAQ:CSTL) Q4 2025 Earnings Call Transcript - Insider Monkey
Castle Biosciences, Inc. (CSTL) Stock Analysis: Unveiling a Promising 50.96% Upside for Investors - DirectorsTalk Interviews
Castle Biosciences (NASDAQ:CSTL) Shares Gap DownWhat's Next? - MarketBeat
Pacira BioSciences Q4 Earnings and Revenues Miss Estimates, Stock Down - Finviz
Castle Biosciences (CSTL) Analyst Rating Update: Baird Raises Pr - GuruFocus
Robert W. Baird Forecasts Strong Price Appreciation for Castle Biosciences (NASDAQ:CSTL) Stock - MarketBeat
Expert Outlook: Castle Biosciences Through The Eyes Of 6 Analysts - Benzinga
Castle Biosciences, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:CSTL) 2026-02-27 - Seeking Alpha
Castle Biosciences, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Castle Biosciences Inc (CSTL) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Challenges - GuruFocus
Transcript : Castle Biosciences, Inc., Q4 2025 Earnings Call, Feb 26, 2026 - marketscreener.com
Castle Biosciences Q4 2025 slides: test volumes surge 42%, enters AD market - Investing.com Nigeria
Volatility Watch: Will Castle Biosciences Inc stock go up in YEAR2025 Bull vs Bear & Free Accurate Trade Setup Notifications - baoquankhu1.vn
Castle Biosciences (NASDAQ:CSTL) Releases Earnings Results - MarketBeat
Castle Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Castle Biosciences (CSTL) Expects Revenue Growth by 2026 - GuruFocus
Castle Biosciences (CSTL) Earnings Transcript - AOL.com
Castle Biosciences, Inc. (CSTL) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance
Castle Biosciences Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Castle Biosciences Q4 2025 beats expectations, stock rises - Investing.com
Earnings Flash (CSTL) Castle Biosciences, Inc. Reports Q4 Revenue $87.0M, vs. FactSet Est of $79.9M - marketscreener.com
Castle Biosciences Posts Modest 2025 Growth Amid Headwinds - TipRanks
Earnings Flash (CSTL) Castle Biosciences, Inc. Posts Q4 Adjusted Loss $0.08 per Share, vs. FactSet Est of $-0.26 - marketscreener.com
Castle Biosciences Reports 37% Increase in Core Test Reports for 2025, Achieving $344 Million in Revenue - Quiver Quantitative
Castle Biosciences (CSTL) swings to 2025 loss as margins compress - Stock Titan
Castle Biosciences Reports Fourth Quarter and Full–Year 2025 Results - GlobeNewswire
Castle Biosciences, Inc. (NASDAQ:CSTL) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Castle Biosciences Stock Hits Day Low of $27.80 Amid Price Pressure - Markets Mojo
Exploring Castle Biosciences's Earnings Expectations - Benzinga
RTW INVESTMENTS, LP Acquires Significant Stake in Castle Bioscie - GuruFocus
Castle Biosciences, Inc. (CSTL) Stock Report: Analysts See 54.98% Potential Upside Amidst Innovative Diagnostics - DirectorsTalk Interviews
Castle Biosciences Publishes Study Demonstrating AdvanceAD-Tx Test Improves Treatment Outcomes for Moderate-to-Severe Atopic Dermatitis Patients - Quiver Quantitative
Prospective Validation Study in JAAD Demonstrates Castle Biosciences’ AdvanceAD-Tx™ Test Identifies Patients More Likely to Achieve Faster and Deeper Responses with JAK Inhibitor Therapy in Moderate-to-Severe Atopic Dermatitis - The Manila Times
1.11%
0.09%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):